Global Chocolate Unwrapped: April Edition: Grinding Through the Data

Core Thesis

The cocoa market is transitioning from a three-year structural deficit to a demand-driven surplus, but inventory rebuild remains fragile. The key investment takeaway is that chocolate manufacturers face a steep pipeline cost reversal – from double-digit inflation in Q1 2026 to >20% deflation by Q2, accelerating through H2 2026. This creates a divergent earnings trajectory: firms with locked‑in hedging positions (Hershey, Mondelez) are positioned to benefit, while those relying on spot or competitive pricing (Barry Callebaut) face sustained margin pressure. The structural decline of West African production share and rising fertilizer input costs add long‑term supply uncertainty, even as near‑term prices ease.

Market Dynamics: Supply Recovery Still Unconvincing

London cocoa cash prices rose +5% and US +6% in April, the smallest monthly move in nearly a year. ICE warehouse inventories increased for the fourth straight month (+12% MoM), yet they remain at only the 19th percentile of the 24‑year history (vs 5th percentile in December). Ivory Coast cumulative arrivals for 2025/26 are flat YoY, but the monthly growth rate slowed from +59% in March to +36% in April, suggesting inventory releases rather than genuine supply upticks. The farmgate price was cut ~60% by the Ivorian regulator, raising long‑term farmer incentive risk. Global tracked grind fell -2% in Q1 2026 (vs -7% in Q4 2025), with Asia turning positive (+5%), but Europe (-8%) and North America (-4%) still contracting. Retail chocolate volumes remain down mid‑single digits in both regions, with pricing still at +13% YoY—consumer resistance persists.

Investment implication: The temporary price stabilization is fragile. Inventory levels, while improving, are historically low. Any supply disruption (weather, disease, farmer disinvestment) could trigger sharp price reversals. The surplus narrative is real but thin.

Company Earnings: Divergent Paths in Cost Management

Earnings season revealed a clear fault line. Mondelez Q1 organic sales beat consensus by +270bps, EPS beat by +9.5%; management explicitly expects cocoa deflation by FY27 and targets chocolate margins back to 2024 levels. Hershey Q1 organic sales beat by +200bps, EPS beat by ~15%; management does not assume further price declines, embedding stable current prices. Both companies have robust hedging programs that lock in cost relief from Q2 2026 onward.

In contrast, Barry Callebaut reported H1 chocolate volumes -5.1% (in line with consensus) but adjusted PBT -9% below expectations, and cut FY26 EBIT guidance to a mid‑teens decline as it invests in competitive pricing. Fuji Oil slashed net profit guidance by -33% due to Blommer goodwill impairment. These companies are more exposed to spot pricing and competitive pressures, unable to capture the same deflation benefit.

Investment implication: The divergence is structural. Companies with long‑dated hedges and pricing power (Mondelez, Hershey) are re‑rating; those forced to compete on price face margin compression. The gap in management’s cocoa price assumptions (Mondelez expecting further decline, Hershey assuming stable) itself creates optionality—whichever assumption proves correct, the direction of cost relief favors the hedged players.

Pipeline Cost Outlook: A Sharp Deflation Turn

The MS Cocoa Pipeline Cost Tracker provides the clearest forward guide. European manufacturer pipeline costs are projected at +13% inflation in Q1 2026, then flipping to -21% deflation in Q2 2026, deepening to -41% in H2 2026. US manufacturers follow a similar trajectory: +9% inflation in Q1 2026, then -16% in Q2, -39% in H2. This is the single most important input for chocolate margins in the next 12 months.

Hershey’s estimated locked‑in cocoa costs show a peak of $7,414/metric ton in Q2 2026, then declining sharply to $3,796 in FY27e. Mondelez shows a peak of £5,410 in Q1 2026, then falling to £2,822 in FY27e. The consensus futures price for US 2026 cocoa remains at $4,731 vs the forward curve at $3,667, implying the market may be over‑estimating costs.

Investment implication: The cost relief is imminent, large, and largely pre‑determined by hedging. Investors should focus on the speed of margin recovery for hedged players, not the spot price direction. Consensus estimates may be too slow to incorporate the magnitude of the Q2‑onward deflation.

Key Risks

Inventory rebuild stalls: ICE stocks at 19th percentile remain vulnerable. A bad mid‑crop or disease outbreak (e.g., Swollen Shoot) could re‑ignite price spikes.
Demand not recovering: European and US grind still negative; retail volumes persistently -4% YoY. If consumers continue to trade down or private label gains share, volume recovery may lag cost relief.
Competitive pricing war: Barry Callebaut’s price cuts and private label’s faster hedging (3–6 months) could pressure brand margins, especially for firms without hedging buffers.
Supply structure shift: West Africa’s share has dropped from 70% to <50% in five years; Ecuador’s output grew >50% in three years. Farmgate price cuts and fertilizer cost surges (+62% YoY in April) risk depressing long‑term output from the traditional heartland.
El Niño recurrence: Lindt’s CFO explicitly flagged El Niño and Swollen Shoot as catalysts that could surprise the market, reversing the current surplus narrative.

Investment Implications

The next six months offer a rare earnings tailwind for chocolate companies with effective hedging programs and pricing power. The cost pipeline data supports a margin expansion thesis for Hershey and Mondelez through FY27, while Barry Callebaut and Fuji Oil face structural headwinds. Investors should position for the deflation turn, but remain alert to supply risks that could flip the surplus story. The divergence between consensus price expectations and the lower forward curve suggests potential upside to cost improvement—and thus to earnings—for well‑hedged names.